CLINICAL OUTCOMES OF PHARMACOKINETICS SERVICES MANAGED BY PHARMACIST AT MINISTRY OF HEALTH HOSPITAL IN SAUDI ARABIA

OBJECTIVES: To explore the clinical outcomes of pharmacist-managed Pharmacokinetics services at Ministry of Health Hospital in Saudi Arabia METHODS: It is a prospective study of pharmacokinetics services impact managed by a pharmacist over a period of six months at King Saud Medical City (KSMC). The...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2017-05, Vol.20 (5), p.A38
Main Authors: Alomi, YA, Almudaiheem, HY
Format: Article
Language:English
Subjects:
Age differences
Clinical outcomes
Compliance
Dosage
Gentamicin
Hospitals
Intervention
Pharmacists
Pharmacokinetics
Pharmacy
Therapeutic drug monitoring
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES: To explore the clinical outcomes of pharmacist-managed Pharmacokinetics services at Ministry of Health Hospital in Saudi Arabia METHODS: It is a prospective study of pharmacokinetics services impact managed by a pharmacist over a period of six months at King Saud Medical City (KSMC). The study divided into two phases, each of 3-month duration for data collection and evaluation. The first phase (Phase I) was the Pre-intervention phase; the second was the intervention phase (phase II). Any patient received Gentamicin followed up by trained pharmacist. The pharmacist all pharmacokinetics parameters such as weight, height, culture sensitivity, and any adjustments in dosage, trough and peak levels and duration of administration recorded on a pharmacokinetics form on a regular basis at each phase. RESULTS: The total number of patients were 162 in phase I and 136 in phase II, the was no difference in age or gender. In the intervention phase, the adherence of labeled indication increased from 67 (41.4%) to 73 (53.7%) patients while adherences of non-labeled indications decreased from 95 (58.6%) to 63 (46.3%) patients. The sub-therapeutic trough levels of Gentamicin statistically significantly decreased from 22(13.6%) to 12 (8.8) patients (p
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2017.05.005